Abpro(ABP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Abpro
ABP.US
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers.
1.955 T
ABP.USMarket value -Rank by Market Cap -/-

Financial Score

23/01/2026 Update
E
BiotechnologyIndustry
Industry Ranking387/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE42.31%A
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-185.64%E
    • Total Assets YoY-49.54%E
    • Net Assets YoY-31.03%E
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio1015.74%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    In Wednesday's pre-market session, Anteris Technologies (NASDAQ:AVR) saw a significant gain of 20.7%, reaching $6.94, with a market cap of $236.8 million. Other gainers included Aditxt (NASDAQ:ADTX) up 20.33% to $1.42, and Abpro Hldgs (NASDAQ:ABP) up 13.26% to $3.5. Conversely, AlphaTON Capital (NASDAQ:ATON) experienced the largest decline, falling 18.7% to $0.75. Other notable losers included INVO Fertility (NASDAQ:IVF) down 15.62% to $2.0, and GlucoTrack (NASDAQ:GCTK) down 14.22% to $3.26.

    benzinga_article·
    US
    ABP
    -11.19%
    benzinga_article·
    US
    ABP
    -11.19%

    Abpro Holdings Receives FDA IND Clearance for ABP-102

    Abpro Holdings Inc. has received FDA IND clearance for its lead oncology program, ABP-102 / CT-P72. This approval allows the company to start a global Phase 1 clinical trial for patients with HER2-positive solid tumors, expected to begin in the first half of 2026 in collaboration with Celltrion.

    Reuters·
    US
    ABP
    -11.19%
    Reuters·
    US
    ABP
    -11.19%

    Abpro Holdings shares are trading higher after the company announced that the FDA has cleared the Investigational New Drug application for its lead multispecific antibody oncology program ABP-102 / CT-P72.

    benzinga_article·
    US
    ABP
    -11.19%
    benzinga_article·
    US
    ABP
    -11.19%

    FDA Clears IND Application for Abpro's Lead Multispecific Antibody Cancer Candidate

    Abpro Holdings Inc. and Celltrion, Inc. have received FDA clearance for their IND application for the multispecific antibody cancer candidate ABP-102 / CT-P72. This approval allows them to start a Phase 1 clinical trial targeting HER2-positive solid tumors, expected to begin in the first half of 2026. The trial will evaluate the therapy's safety, tolerability, pharmacokinetics, and preliminary efficacy as part of a global collaboration between the companies.

    Reuters·
    US
    ABP
    -11.19%
    Reuters·
    US
    ABP
    -11.19%

    Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

    ABPRO Holdings Inc :ABPRO HOLDINGS ANNOUNCES SUBMISSION OF AN IND APPLICATION TO INITIATE A PHASE 1 CLINICAL TRIAL OF T CELL ENGAGER ABP-102/CT-P72 FOR HER2-POSITIVE CANCERSABPRO HOLDINGS INC - PHASE 1 TRIAL FOR HER2-POSITIVE CANCERS EXPECTED IN 1H 2026

    Reuters·
    US
    ABP
    -11.19%
    Reuters·
    US
    ABP
    -11.19%
    © 2026 Longbridge｜Disclaimer